OraSure Technologies (NASDAQ:OSUR) is scheduled to announce its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. OraSure Technologies has set its Q2 guidance at approx $0.02 EPS and its FY19 guidance at $0.22-0.24 EPS.Investors interested in registering for the company’s conference call can do so using this link.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. OraSure Technologies had a net margin of 11.34% and a return on equity of 7.87%. The firm had revenue of $30.12 million for the quarter, compared to analysts’ expectations of $29.66 million. During the same quarter in the prior year, the business earned $0.07 EPS. The business’s quarterly revenue was down 28.3% on a year-over-year basis. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ OSUR traded down $0.19 on Tuesday, reaching $8.36. 23,374 shares of the stock were exchanged, compared to its average volume of 441,549. OraSure Technologies has a one year low of $8.01 and a one year high of $17.20. The firm has a market cap of $534.88 million, a price-to-earnings ratio of 16.68, a PEG ratio of 3.00 and a beta of 1.21. The firm’s 50-day moving average price is $8.77. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.52 and a quick ratio of 6.56.
In other news, CFO Roberto Cuca bought 10,000 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were bought at an average price of $9.03 per share, for a total transaction of $90,300.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have acquired 21,000 shares of company stock worth $184,360. 1.70% of the stock is owned by company insiders.
A number of equities research analysts have commented on OSUR shares. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Canaccord Genuity restated a “hold” rating and set a $20.00 target price (down previously from $29.00) on shares of Sailpoint Technologies in a research note on Thursday, May 9th. Finally, BidaskClub upgraded shares of WhiteHorse Finance from a “sell” rating to a “hold” rating in a research note on Thursday, July 18th. Three analysts have rated the stock with a sell rating and one has given a hold rating to the company’s stock. The company currently has an average rating of “Sell” and an average target price of $10.00.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.